ALLORION THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1/2 STUDY OF ARTS-021, A POTENTIAL BEST IN CLASS CDK2 INHIBITOR, FOR ADVANCED OR METASTATIC SOLID TUMORS

About AllorionAllorion Therapeutics is a biotechnology company that focuses on creating new small molecule drugs for treating cancer and autoimmune diseases. The company has a team of experienced drug discovery and development professionals who identify new drugs with unique mechanisms of actions and develop innovative data and screening platforms for long-term success. Allorion Therapeutics aims to advance new drugs with high potential and clinical relevance. About Allorion Allorion...

NATICK, Mass., 12/10/2023 (informazione.news - comunicati stampa - scienza e tecnologia)

About Allorion
Allorion Therapeutics is a biotechnology company that focuses on creating new small molecule drugs for treating cancer and autoimmune diseases. The company has a team of experienced drug discovery and development professionals who identify new drugs with unique mechanisms of actions and develop innovative data and screening platforms for long-term success. Allorion Therapeutics aims to advance new drugs with high potential and clinical relevance.

About ARTS-021
ARTS-021 is a highly potent and selective inhibitor of CDK2, a key enzyme involved in cell cycle regulation. ARTS-021 can selectively inhibit the growth of tumor with CCNE1 amplification in preclinical studies. It can also overcome the resistance that ER+/HER2- breast cancer cells develop against CDK4/6 inhibitors.

Logo - https://mma.prnewswire.com/media/2245014/4336020/Allorion_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/allorion-therapeutics-announces-first-patient-dosed-in-phase-12-study-of-arts-021-a-potential-best-in-class-cdk2-inhibitor-for-advanced-or-metastatic-solid-tumors-301954358.html